Sexually Transmitted Disease

Anti-Herpes compound license agreement exercised

Published in AIDS Weekly, September 22nd, 2003

CytoGenix, Inc., (CYGX) announced that Phanuel Pursuits, LLC (USVI) has exercised its option for an exclusive license for the manufacture and distribution of CytoGenix' proprietary anti-herpes topical cream in the People's Republic of China and also obtained an additional option for a similar arrangement for India.

Both countries are experiencing rapidly increasing incidences of sexually transmitted diseases (STDs). With a total 2.3 billion people, India and China have about 40% of world's population. Based on U.S. genital infection rates of 1 in 4 adults, an estimated 575,000,000 people in China and India could be infected.

"We will work closely...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2003-09-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry